Manfred Beier

Overview

Explore the profile of Manfred Beier including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 22

Citations 336

Followers 0

Related Specialties

Oncology

Molecular Biology

Genetics

Top 10 Co-Authors

Brigitte Royer-Pokora

Hans-Dieter Royer

Maike Busch

Nicole Dunker

Barbara Hildebrandt

Artur Brandt

Jaume Mora

Klaus Metz

Maike Anna Busch

Eva Biewald

Published In

Am J Med Genet A

Cancer Genet Cytogenet

PLoS One

Cancers (Basel)

Hum Mol Genet

Affiliations

Soon will be listed here.

Recent Articles

11.

Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15

Brandt A, Lohers K, Beier M, Leube B, de Torres C, Mora J, et al.

PLoS One . 2016 May; 11(5):e0155561. PMID: 27213811

We describe a stromal predominant Wilms tumor with focal anaplasia and a complex, tumor specific chromosome 11 aberration: a homozygous deletion of the entire WT1 gene within a heterozygous 11p13...

12.

Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation

Busch M, Schwindt H, Brandt A, Beier M, Gorldt N, Romaniuk P, et al.

Hum Mol Genet . 2014 Mar; 23(15):3958-74. PMID: 24619359

The WT1 gene encodes a zinc finger transcription factor important for normal kidney development. WT1 is a suppressor for Wilms tumour development and an oncogene for diverse malignant tumours. We...

13.

A novel inverted 17p13.3 microduplication disrupting PAFAH1B1 (LIS1) in a girl with syndromic lissencephaly

Classen S, Goecke T, Drechsler M, Betz B, Nickel N, Beier M, et al.

Am J Med Genet A . 2013 May; 161A(6):1453-8. PMID: 23633430

We describe a female patient with mild lissencephaly (pachygyria), severe intellectual disability, and facial dysmorphisms with an inverted 1.4 Mb microduplication of chromosome 17p13.3. The 17p13.3 microduplication syndrome is associated...

14.

Evaluation of chromosome 11p imbalances in aniridia and Wilms tumor patients

Busch M, Leube B, Thiel A, Schanze I, Beier M, Royer-Pokora B

Am J Med Genet A . 2013 Mar; 161A(5):958-64. PMID: 23494989

Newborn sporadic aniridia patients with an 11p13 deletion including the WT1 gene have an increased risk to develop Wilms tumor. At present a risk for Wilms tumor cannot be estimated...

15.

Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling

Koch M, Krieger M, Stolting D, Brenner N, Beier M, Jaehde U, et al.

Biochem Pharmacol . 2013 Feb; 85(8):1077-90. PMID: 23396090

Previously we reported that liposomal cisplatin (CDDP) overcomes CDDP resistance of ovarian A2780cis cancer cells (Krieger et al., Int. J. Pharm. 389, 2010, 10-17). Here we find that the cytotoxic...

16.

Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm

Royer-Pokora B, Busch M, Beier M, Duhme C, de Torres C, Mora J, et al.

Hum Mol Genet . 2010 Jan; 19(9):1651-68. PMID: 20106868

Wilms tumors (WTs) are genetically heterogeneous kidney tumors whose cells of origin are unknown. Tumors with WT1 mutations and concomitant loss of the wild-type allele represent a distinct subgroup, frequently...

17.

Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells

Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S, et al.

Cancer Res . 2009 Mar; 69(7):2996-3003. PMID: 19318572

Platinum plays a central role in the therapy of ovarian cancer, and the emergence of platinum resistance is a major obstacle for clinical management of the disease. We treated A2780...

18.

Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric...

Royer-Pokora B, Weirich A, Schumacher V, Uschkereit C, Beier M, Leuschner I, et al.

Cancer . 2008 Jul; 113(5):1080-9. PMID: 18618575

Background: Mutations in the Wilms tumor (WT) suppressor 1 gene (WT1) and the cadherin-associated protein beta1 gene (CTNNB1) are found predominantly in stromal type WT, defining a genetic subgroup. The...

19.

Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH

Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M, et al.

Genes Chromosomes Cancer . 2007 Sep; 46(12):1119-28. PMID: 17823930

Isolated deletions of the long arm of chromosome 5, del(5q), are observed in 10% of myelodysplastic syndromes (MDS) and are associated with a more favorable prognosis, although the clinical course...

20.

Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia

Royer-Pokora B, Trost D, Muller N, Hildebrandt B, Germing U, Beier M

Cancer Genet Cytogenet . 2006 May; 167(1):66-9. PMID: 16682289

Deletions of 5q in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are of different extents and the majority map to sub-bands 5q13.3 and 5q33.1. To further pinpoint these deletions,...